Dividend investing is a proven way to earn above-average long-term returns. That's why top dividend stocks often attract large crowds of investors and trade at a premium. However, it's possible to find quality income stocks that are reasonably -- or even attractively -- valued, perhaps because they have faced challenges from which they will recover, but the market has yet to catch on.
Let's consider two dividend stocks that fit this description: Pfizer (PFE +1.45%) and Bristol Myers Squibb (BMY +2.24%). For dividend seekers with $1,000 to spare -- that isn't saved for bills or emergencies -- here's why it would be a great idea to invest in these stocks.
Image source: The Motley Fool.
1. Pfizer In 2022, Pfizer became the first biopharmaceutical company to reach $100 billion in annual sales, mostly due to its dominance in the coronavirus market. But it's been pretty much downhill from there. The drugmaker was unable to sustain solid revenue from its COVID-19 products as vaccination and hospitalization rates declined. Also, Pfizer will face important patent cliffs by the end of the decade. The company's anticoagulant Eliquis, which it shares the rights to with Bristol Myers, will lose patent exclusivity.
It's not surprising, then, that the company has lagged broader equities recently. However, the next five years could be transformational for the pharmaceutical giant as it advances important pipeline candidates. Pfizer has a deep pipeline, and multiple "shots on goal" should allow it to launch brand-new, highly successful products, eventually, even amid occasional clinical setbacks.
Today's Change
(
1.45
%) $
0.35
Current Price
$
24.07
The company's oncology pipeline looks particularly attractive, with candidates such as PF'4404, an investigational medicine in a newer class of cancer drugs, bispecific antibodies. Unlike traditional monoclonal antibodies, the current standards of care in oncology, which target one disease marker, bispecific antibodies can target two at the same time, often making them more effective at finding and destroying cancer cells. Pfizer thinks PF'4404 could be a pipeline-in-a-drug, earning approval across several market niches.
The medicine is currently in phase 3 studies and could deliver important clinical wins in the coming years. And it's just one of many promising candidates in Pfizer's oncology pipeline. The company is also making solid progress with its weight loss pipeline, with some candidates currently in phase 3 studies. Meanwhile, even though Pfizer's financial results haven't been great, some of its products are performing well and should help push sales higher for the foreseeable future. The company's bladder cancer drug Padcev and its respiratory syncytial virus vaccine, Abrysvo, are good examples.
Pfizer's strong pipeline and resilient underlying business (despite some headwinds) mean it is unlikely to cut its dividend. It currently offers a forward yield of 7.1% and has increased its payouts by 51.3% over the past decade. Lastly, the stock is trading at just 8.2x forward earnings, versus an average of 18.2 for healthcare stocks. This blue chip dividend stock looks like a strong buy at current levels. And with $1,000, investors can buy 42 shares of Pfizer.
2. Bristol Myers Squibb After facing some patent cliffs in recent years, Bristol Myers has gotten back on the right track. The company's revenue is moving in the right direction again, albeit slowly. However, the pharmaceutical leader will face more patent cliffs by the end of the decade, notably for two of its best-selling drugs, Eliquis and Opdivo, a cancer medicine. Bristol Myers seems well-equipped to replace those two drugs and has already taken important steps in that direction, with the approval of a subcutaneous version of Opdivo that will contribute to its top-line well into the next decade.
Today's Change
(
2.24
%) $
1.27
Current Price
$
57.97
Elsewhere, Bristol Myers is partnering with Johnson & Johnson (JNJ +3.05%) to develop Milvexian, a next-gen anticoagulant that aims to be just as effective as competitors while avoiding the bleeding risk associated with typical anticoagulants. Milvexian has received the Fast Track Designation from the U.S. Food and Drug Administration, a program that helps expedite the review and approval of drugs that treat serious conditions and address a high unmet need.
This suggests that the data so far indicate Milvexian could be just as good as advertised. Further, Bristol Myers is looking to get into the bispecific antibody market and is working on a promising candidate, pumitamig, with BioNTech (BNTX +0.38%). Expect solid progress from these (and other) candidates in the next couple of years. And in the meantime, even with the looming major patent cliffs, Bristol Myers has a portfolio of newer launches that are performing well and should eventually help replace older medicines.
The company isn't at risk of cutting its dividend. Bristol Myers' forward yield is 4.3%, and it has increased its payouts by 65.8% over the past decade. Finally, with the stock trading at 9x forward earnings, now is a great time to buy. $1,000 is good for 17 shares at the stock's current price.
Hub Group, Inc. (HUBG) Faces Securities Class Action -- Hagens Berman Investigates Claims of False Financial Reporting PR Newswire
SAN FRANCISCO, July 7, 2026
, /PRNewswire/ -- Hub Group, Inc. (NASDAQ: HUBG) and certain of its current and former executives (together, "co-defendants") face a securities class action lawsuit, which seeks to represent investors who purchased or acquired Hub Group securities between April 28, 2023 and May 11, 2026.
The development follows the company's surprise revelations that its financial reports going back to 2023 were "materially misstated and should no longer be relied upon" and corrective actions taken against two senior executives.
National shareholder rights firm Hagens Berman continues to investigate legal claims that Hub Group and its co-defendants violated the federal securities laws and urges investors who suffered significant losses to submit your losses now.
Class Period: Apr. 28, 2023 – May 11, 2026
Lead Plaintiff Deadline: Aug. 28, 2026
Visit: www.hbsslaw.com/investor-fraud/hubg
Contact the Firm Now: [email protected]
844-916-0895
Hub Group, Inc. (HUBG) Securities Class Action:
The lawsuit focuses on the propriety of Hub Group's repeated assurances that its financial statements were prepared in conformity with applicable accounting rules.
Contrary to these assurances, the complaint alleges that throughout the Class Period the co-defendants made false and misleading statements concerning Hub Group's premature and incorrect revenue recognition and understatement of purchased transportation costs and accounts payable.
Investors learned the truth through a series of Hub Group's partial disclosures about its accounting and ramifications for certain of its executives.
First, on February 6, 2026, investors saw the price of their Hub Group shares crater $9.37 (-18%) after the company (while touting that "[a]ccuracy and transparency in reporting on our performance is of utmost importance[]") revealed that during the first nine months of 2025 it had understated purchased transportation costs and accounts receivable by $77 million. Accordingly, the company said investors should not rely on its Q1 – Q3 2025 financial statements and it plans to restate them.
Second, on May 12, Hub Group shares tumbled again – this time, shares fell $5.24 (-12.5%) – on new disclosures much worse than on February 6. The company said its financial statements for the years ended December 31, 2023 and 2024 were materially misstated and that investors should no longer rely on those either. Hub Group explained only that it "identified certain transactions that were prematurely or incorrectly recognized or not adequately supported[]" and cautioned it was continuing to review "additional accounting issues that may potentially further impact" the 2023 and 2024 financial statements.
Between February 5, 2026 (the day before Hub Group's first partial corrective disclosure) and May 12, 2026, shareholders have seen over $890 million of Hub Group's market capitalization wiped out.
After the Class Period, on June 2, 2026, Hub Group announced that Chief Financial Officer Kevin Beth and Chief Operating Officer Brian Meents both left the company on May 27. The company said the executive departures were part of its corrective actions related to its financial statement review.
"Now that Hub Group has almost cleaned out its C-suite following accounting improprieties reaching all the way back to 2023, the core focus of our investigation is whether they were intentional or reckless with the goal of making financial metrics appear better than they actually were. We're also looking to see whether additional problems will surface when the company's review is completed," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in Hub Group and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »
If you'd like more information and answers to other frequently asked questions about the Hub Group case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding Hub Group should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hub-group-inc-hubg-faces-securities-class-action--hagens-berman-investigates-claims-of-false-financial-reporting-302820091.html
New York, New York--(Newsfile Corp. - July 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of purchasers of securities of Hub Group, Inc. (NASDAQ: HUBG) between April 28, 2023 and May 11, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 28, 2026.
SO WHAT: If you purchased Hub Group securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that Hub Group's financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements-caused by the premature and incorrect recognition of certain transactions-concerning, inter alia, Hub Group's operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth. In addition, Hub Group's financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements-caused by the understatement of purchased transportation costs and accounts payable -concerning, inter alia, Hub Group's operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Hub Group class action, go to https://rosenlegal.com/cases/hub-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304298
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
HCA Healthcare remains a soft 'buy' despite recent underperformance, with fundamentals improving and shares attractively priced on an absolute basis. HCA's revenue and profitability continue to grow, driven by Medicare/Medicaid, increased equivalent admissions, and higher revenue per admission, even as the physical footprint shrinks. Management sustains shareholder returns through dividends and aggressive buybacks, with a 6.9% reduction in share count and $9.18 billion in remaining buyback capacity.
Mid-cap stocks MYR Group (MYRG 5.06%) and VSE Corporation (VSEC 7.12%) operate in completely different industrial sectors, with MYR Group focusing on electrical contracting and VSE on aviation aftermarket services.
However, they are fundamentally cut from the same cloth, as they rely heavily on recurring, non-discretionary service revenue. Utilities must maintain the grid, and that's where MYR comes in. Planes must be serviced to remain airworthy, which is how VSE generates income.
As of July 6, VSE's shares are up more than 38% this year, and MYR's shares are up more than 102%. Here are three reasons why I still like each of these pick-and-shovel stocks.
Image source: Getty Images.
MYR Group benefits from the data center supercycle The company is well-positioned for the massive multi-year build-out of data centers, renewable energy integration, and electric vehicle (EV) charging infrastructure. Because its commercial and industrial (C&I) segment specializes in complex electrical contracting, it is seeing intense demand from tech companies expanding their artificial intelligence (AI) infrastructure. Additionally, utility companies face a multi-decade grid modernization cycle to handle higher power loads and connect new clean energy sources, giving MYR Group a structural tailwind that isn't reliant on normal economic cycles.
Today's Change
(
-5.06
%) $
-22.39
Current Price
$
420.33
Double-digit revenue and earnings growth MYR Group's execution is translating into rapid earnings growth. In the first quarter, revenue was reported as $1 billion, up 20% year over year, led by strong growth from its transmission and distribution segment. Earnings per share (EPS) jumped 106% over the same period last year to $2.99. Consolidated gross margins expanded to 13.4% (up from 11.6% the prior year), fueled by excellent productivity, favorable project closeouts, and shifting to higher-margin project mixes.
Record backlog for MYR and expansion MYR Group provides incredible long-term revenue visibility. It ended Q1 with a record backlog of $2.84 billion (up nearly 8% year over year). To capitalize on this pipeline, the company is aggressively expanding via acquisition. In May, MYR entered a definitive agreement to acquire Valley Electric and Comet Electric for $328 million. This strategic move heavily scales its C&I presence in the Western United States, giving it immediate local market share to capture sweeping infrastructure projects across the coast.
VSE's acquisitions should drive growth In May, VSE closed a $2 billion acquisition of Precision Aviation Group. This deal is a game changer that dramatically expands VSE's global footprint, scaling its maintenance, repair, and overhaul (MRO) capabilities to 61 locations across eight countries. The business is expected to be immediately accretive to VSE's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin.
In April, VSE bought NorthStar Technologies, a provider of MRO and third-party logistics services supporting the engine aftermarket. NorthStar specializes in teardown, kitting, and other labor- and technically intensive services across multiple engine platforms. The acquisition enhances VSE's position within original equipment manufacturer (OEM) aftermarket supply chains.
Today's Change
(
-7.12
%) $
-16.95
Current Price
$
221.06
VSE is seeing strong earnings growth Thanks to massive demand in commercial engine aftermarket sales and exclusive long-term OEM distribution agreements, VSE is seeing strong revenue and earnings growth.
In Q1, it reported revenue of $324.6 million, up 26.8% year over year, and earnings per share (EPS) of $1.04, up 55.2% over the same period a year ago. The company's recent acquisitions led VSE to boost its yearly forecast. It now expects full-year revenue to grow from 57% to 61%, compared to earlier guidance of 19% to 23%. It also increased its estimated adjusted EBITDA to 18.1% to 18.5%, up from earlier estimates of 16.8% to 17.3%.
A highly resilient business mix insulated from macro risks VSE operates in a strategic sweet spot within the aviation aftermarket. Roughly 48% of its exposure is in business jets and general aviation, with about a 50% focus specifically on engine components. This mix makes VSE highly resilient to macroeconomic headwinds, such as fluctuating commercial airline demand, fuel price spikes, or geopolitical conflicts.
John Cuomo, VSE's president and CEO, said that as it integrates Precision Aviation Group and realizes cost synergies, the company is targeting long-term adjusted EBITDA margins of more than 20%. This means that the company is becoming substantially more profitable as it scales.
The rewards outweigh their risks MYR's biggest concern is its exposure to fixed-price contracts, particularly in its C&I business. However, despite the fixed-price nature of its backlog, consolidated gross margins recently expanded to a record 13.4% as the company shifts away from low-margin clean energy projects toward high-margin data center and grid modernization infrastructure.
VSE's big concern is that it took on substantial debt to purchase Precision Aviation Group. If integrating that business hits operational bottlenecks, cost overruns, or corporate friction, it could delay the synergy timeline and pinch near-term cash flows. However, Precision Aviation brings highly predictable, immediately cash-accretive cash flows, which should enable VSE to quickly pay down its debt.
Vertex Pharmaceuticals (VRTX 1.31%) is making its biggest bet in years. On Monday, the company agreed to acquire Crinetics Pharmaceuticals (CRNX +98.74%) for $85 per share in cash. That works out to a total equity value of about $10 billion, or roughly $8.8 billion net of the cash Crinetics holds. Both companies' boards approved the deal unanimously, and Vertex expects it to close in the third quarter of 2026.
For a company that has spent decades built almost entirely around cystic fibrosis, this is a meaningful step into a new disease area. Here's what the deal buys, how Vertex is paying for it, and whether the price looks reasonable.
Image source: Getty Images.
What Crinetics brings Perhaps the biggest asset Crinetics brings is a drug called PALSONIFY -- the first and only once-daily oral therapy approved for adults with acromegaly. It won U.S. approval in September 2025 and was recently cleared in Europe. Vertex says its early launch has shown strong demand across patient groups. Until PALSONIFY arrived, most patients relied on large-needle injectable treatments, so an oral option fills a real gap.
Behind it sits atumelnant, a once-daily oral drug in late-stage development for congenital adrenal hyperplasia, another rare endocrine condition. The drug has also shown early promise in Cushing's syndrome.
Together, Vertex says these assets boast more than $5 billion in combined annual peak-sales potential.
Crinetics notably also brings a drug-discovery platform focused on endocrine diseases -- a pipeline of earlier-stage programs, and intellectual property protection that extends into the 2040s.
How Vertex is paying for it This is an all-cash deal, and Vertex isn't paying entirely out of pocket. The company plans to fund the purchase with a mix of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing from Bank of America and Morgan Stanley.
Vertex can afford it. The company held about $13 billion in cash and marketable securities at the end of the first quarter, and its base cystic fibrosis business keeps generating substantial cash. First-quarter revenue rose 8% year over year to about $3 billion, and the company reaffirmed full-year guidance of roughly $13 billion. Layering some debt on top to close a $10 billion acquisition is well within reach for a company generating this kind of recurring cash flow.
It helps that Vertex isn't overleveraging itself. The bridge financing is meant to be temporary, refinanced over time rather than left on the balance sheet as permanent leverage. In other words, this is a well-capitalized business adding to its portfolio.
Today's Change
(
-1.31
%) $
-6.94
Current Price
$
522.65
Whether the price is disciplined Here's the part that matters most for Vertex shareholders. At $85 per share and more than $5 billion in combined peak-sales potential, Vertex is paying about two times peak sales. And peak sales, by definition, are years away and far from guaranteed. Atumelnant is still in trials, and even PALSONIFY's launch is only a few quarters old.
Vertex acknowledges the timeline. It expects the deal to become accretive to non-GAAP (adjusted) operating income only in 2029, though it says PALSONIFY's ongoing launch should start adding to revenue right away.
Even so, there is a solid case that the price is fair. Vertex isn't a serial acquirer reaching outside its expertise. It's buying assets that fit its stated strategy of targeting serious diseases with well-understood biology, small commercial footprints, and high unmet need. That is the same profile that made its cystic fibrosis franchise so profitable. The deal also solves a real problem. Vertex needs growth engines beyond cystic fibrosis, and building a new specialty franchise from scratch would take far longer than buying one with an approved, launching drug.
So, is this a smart deal for Vertex?
Overall, I think it's a reasonable one. But the company is paying full price for assets whose biggest payoffs are still ahead. That said, Vertex is buying under a strategy it knows well, using a balance sheet that can absorb the cost, and addressing its diversification needs in a single move. So, for a business that has long needed a second act, paying up for a new growth pillar looks like a solid idea. Now we just need the pipeline to deliver.
"Buy low" is a common investing phrase that some people may interpret as "buy after a pullback." However, even near all-time highs, a stock can be at a "low" point, provided there are good reasons to think it will continue performing well. That's why buying shares of companies that have risen significantly recently isn't necessarily a bad idea. With that said, let's consider three stocks that have all more than doubled over the trailing-12-month period but may have plenty more fuel in the engine to keep going: Abivax (ABVX 1.26%), Krystal Biotech (KRYS 1.51%), and Marvell Technology (MRVL 7.45%).
Image source: Getty Images.
1. Abivax Shares of Abivax are up by more than 1,500% over the past 12 months. As is usually the case with clinical-stage biotechs, the company owes this performance to strong clinical progress with its leading candidate, obefazimod, an investigational medicine for ulcerative colitis (UC). Obefazimod has now shown strong efficacy results as both an induction and maintenance therapy for patients with moderate-to-severe UC. And although initial data from the maintenance trial raised some safety concerns, the company has addressed them as well.
Today's Change
(
-1.26
%) $
-1.82
Current Price
$
142.17
The inflammatory bowel disease market -- which includes UC and Crohn's disease -- is large and typically dominated by pharmaceutical giants. But Abivax could make a dent in this field. Unlike many immunosuppressants used to treat UC, obefazimod doesn't work by weakening the immune system, which leaves patients at risk of infections. Further, it is an oral pill, which makes it more convenient than many therapies administered subcutaneously. Abivax is planning to submit an application for approval by the end of 2026. It is also testing its lead candidate in a phase 2 clinical trial for Crohn's disease.
Positive data from this study could send the stock even higher. Naturally, there are some risks, including the possibility of clinical and regulatory setbacks that drugmakers -- especially smaller ones -- encounter. However, given the incredible potential of obefazimod, Abivax looks like an intriguing play. There may be plenty of upside left for the stock.
2. Krystal Biotech Krystal Biotech is performing well thanks to Vyjuvek, the first medicine approved to treat dystrophic epidermolysis bullosa (DEB), a rare genetic disease that causes extremely fragile skin that can be injured even from minor friction. This therapy is helping Krystal Biotech deliver strong financial results. In the first quarter, the company's revenue was $116.4 million, entirely from its only approved product, up 32% from the year-ago period. Krystal Biotech reported a net profit of $55.9 million, up 56.5% year over year.
Today's Change
(
-1.51
%) $
-5.67
Current Price
$
369.01
Krystal Biotech still has a large addressable market for Vyjuvek. After launching the medicine abroad, the company reported at the beginning of the year that over 90 patients had been prescribed Vyjuvek across Japan, France, and Germany. However, the company is looking at an opportunity of more than 1,300 patients in these three markets. So, we should see Krystal Biotech's sales and earnings continue to move in the right direction for a while. Elsewhere, the company is developing other products across various diseases.
Krystal Biotech has a fairly deep pipeline for a drugmaker of its size, and we could see strong clinical and regulatory progress from the company over the next five years. The stock has climbed 167% over the past 12 months, but it may not have peaked yet.
3. Marvell Technology Marvell Technology designs Application-Specific Integrated Circuits (ASICs), or custom chips, tailored to specific workloads. With the artificial intelligence (AI) industry still in high-growth mode, ASICs are increasingly in high demand. Here are two reasons why. First, although they may not be as versatile as market-leading GPUs (Graphics Processing Units), they are often more cost-efficient for specific workloads and can help companies reduce expenses when deployed at scale.
Second, with Nvidia (NVDA +0.62%) still dominating the GPU market, corporations have been looking to decrease their reliance on its hardware to avoid supply constraints.
Marvell Technology is benefiting from this, and the company's sales and earnings are increasing rapidly as a result. In the first quarter of its fiscal year 2027, ending May 2, Marvell's net revenue reached a record $2.4 billion, up 28% year over year. The company's data center segment accounted for 76% of its revenue. Meanwhile, its adjusted earnings per share rose 29% year over year to $0.80.
Today's Change
(
-7.45
%) $
-18.57
Current Price
$
230.70
This may only be the beginning for Marvell. As AI infrastructure spending grows over the next few years, some of that spending will flow directly into the pockets of ASIC makers. In fact, the company expects year-over-year top-line growth to accelerate in every quarter of its ongoing fiscal year, signaling that demand for its products is increasing. Marvell could ride this tailwind for a while and generate more market-beating returns. Don't ignore the stock just because it has soared 248% over the past 12 months.
, /PRNewswire/ -- Hagens Berman (HBSS), a securities litigation leader, is broadening its investigation into Verra Mobility Corp. (NASDAQ: VRRM) following the company's disclosure of an abrupt leadership transition. The news comes in the wake of a securities action suit stemming from the catastrophic loss of a major contract.
VRRM Investors Submit Your Losses Now to HBSS
Class Period: Feb. 24, 2026 – May 26, 2026
Lead Plaintiff Deadline: Aug. 4, 2026
Visit: www.hbsslaw.com/investor-fraud/vrrm
Contact the Firm Now: [email protected]
844-916-0895
Leadership Vacuum
On June 1, 2026, Verra Mobility announced that long-time CEO David Roberts has abruptly stepped down, ending a 12-year tenure. This departure follows a volatile period for the company, initiated by the unexpected termination of a key contract with Avis Budget Group—a move that wiped out approximately $1.4 billion in shareholder value.
The Board of Directors has appointed former Chief Transformation and Legal Officer Jon Keyser as interim President and CEO while retaining a global search firm for a permanent replacement. Hagens Berman is investigating whether the departure is causally related to the allegations in the securities class action suit.
Verra Mobility Corporation (VRRM) Securities Class Action:
The complaint alleges Verra made false and misleading statements and did not disclose important information to investors about the true state of the Verra/Avis relationship and the likelihood of Verra receiving an Avis contract renewal.
The truth allegedly emerged on May 26, 2026, when Verra disclosed that it received a termination notice effective September 2026 from Avis regarding the companies' contract, that it is taking immediate actions to cut costs, adapt operations, and reposition its business, and revised its 2026 outlook that significantly deviated from that given just twenty days prior.
Verra also revealed that it was reviewing the parties' negotiations and handling of confidential information.
The news promptly sent the price of Verra shares 70% crashing lower on May 27, 2026, amputating $1.4 billion from the company's market capitalization in a single day.
View our latest video summary of the allegations: youtu.be/FVEw5XACoGA
"Our investigation is focused on the extent to which and when Verra and its executives knew that renegotiations with Avis were far from constructive, as the May 26 surprise reveals," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in Verra and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now.
If you'd like more information and answers to other frequently asked questions about the Verra case and the firm's investigation, read more.
Whistleblowers: Persons with non-public information regarding Verra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Pinnacle West Capital Corp. (NYSE: PNW) announced today that it plans to release its 2026 second-quarter financial results before U.S. financial markets open o
Shares of Circle Internet Group (CRCL 5.10%) fell 44.6% in June 2026, according to data from S&P Global Market Intelligence. For the first week of that month, Circle's stock followed Bitcoin (BTC 1.54%) lower, but at an exaggerated pace. That's life in the crypto sector, even if Circle chiefly manages the popular stablecoin USD Coin (USDC 0.01%).
The stock ended June with a single-day plunge of 17.6%. That sudden drop sprang from two concurrent catalysts. A coalition of big-name businesses teamed up to launch the Open USD (OUSD 0.02%) stablecoin, threatening Circle's core business directly. At the same time, Circle's stock was removed from five Russell indexes, forcing several funds to drop the stock.
Today's Change
(
-5.10
%) $
-3.50
Current Price
$
65.15
Strategy's tiny Bitcoin sale spooked the whole market Bitcoin's price drop reflected economic turbulence, a risk-off investor mood, and unexpected pressure from Strategy (MSTR 3.38%). The world's largest holder of Bitcoin sold 0.4% of its holdings to fund operations in U.S. dollars.
The company is still the top Bitcoin owner with 843,775 coins, ahead of the iShares Bitcoin Trust ETF (IBIT +0.08%) at 811,291 and the U.S. Bitcoin Treasury with 328,372. But Strategy's executive chairman, Michael Saylor, is known for his maximalist approach to Bitcoin and has promised to continue accumulating it.
So crypto investors are nervous that even Saylor is selling a handful of coins these days. The move unnerved traders across the board, including stablecoin issuers. Due to a rich valuation and high volatility, Circle's stock tends to skyrocket when Bitcoin says "jump," but crash when Bitcoin stumbles.
And then there's the new stablecoin in town. The upcoming launch (scheduled for "later this year") has the backing of financial giants like Visa (V 1.37%) and BlackRock (BLK 0.23%), fintech experts including Klarna (KLAR 2.31%) and Affirm (AFRM 2.52%), as well as tech titans Alphabet (GOOG 0.25%) (GOOGL +0.25%) and Samsung Electronics (SSNLF +0.00%).
If USD Coin is the digital version of a private commercial bank issuing its own currency (always worth one dollar per coin), the Open USD stablecoin is trying to be the digital equivalent of Visa or the SWIFT interbank payment system. It's a neutral, utility-style network backbone owned and operated by the very institutions that use it.
And it seems destined to grab market share and profits from Circle's USD Coin in the process.
Image source: The Motley Fool.
What Circle investors should do now So, where does this leave Circle? Somewhere between "fine" and "sweating a little."
The Open USD initiative brings deep-pocketed competitors into a market where USD Coin currently holds roughly 26% share, second only to Tether (USDT 0.01%). Meanwhile, the Russell index removals reduce passive fund demand for Circle's stock at a time when crypto sentiment remains fragile.
But Circle still runs one of the most trusted stablecoins on the planet. Regulatory clarity has been a tailwind, and USD Coin's reputation for transparency is valuable.
Investors should watch for Circle's response to the looming Open USD challenge. The company could pursue partnerships of its own, lean into regulatory advantages, or expand beyond stablecoin issuance into adjacent services. For now, though, the stock remains chained to Bitcoin's whims and haunted by that shiny new competitor on the horizon.
Circle isn't going away, but its competitive moat is drying out. It's time to circle the wagons.
Anders Bylund has positions in Alphabet, Bitcoin, and iShares Bitcoin Trust. The Motley Fool has positions in and recommends Alphabet, Bitcoin, BlackRock, Klarna Group, Visa, and iShares Bitcoin Trust. The Motley Fool has a disclosure policy.
U.S. airlines spent $6.66 billion on jet fuel in May, the second straight month that fuel costs topped $6 billion, according to government data released Tuesday.
The May figure was 84% higher than a year earlier.
Airlines spent $6.47 billion on fuel in April, the Bureau of Transportation Statistics said.
The latest government data reveals that U.S. airlines spent $6.66 billion on jet fuel in May 2026. AP Photo/Carolyn Kaster The higher year-over-year spending has been driven mostly by pricier jet fuel rather than a significant increase in how much of it airlines consumed.
U.S. carriers used 1.627 billion gallons in May, down 0.6% from May 2025.
Consumption was also slightly lower in April compared with a year earlier.
The average price airlines paid for fuel in May was $4.09 per gallon, down slightly from $4.11 in April but 85% higher than the $2.21 they paid in May 2025, the agency said.
Airlines worldwide have responded to the jump in fuel prices by raising fares and fees and trimming flight schedules.
The Bureau of Transportation Statistics also revealed that airlines spent $6.47 billion on fuel in April 2026. AP Photo/LM Otero Fuel is typically one of the industry’s largest operating costs, leaving carriers particularly vulnerable to swings in energy prices.
The latest figures show the continued impact of the sharp rise in energy costs after the conflict in the Middle East started this year and disrupted shipping through the Strait of Hormuz, a key route for global crude and fuel supplies.
Fuel prices have eased from their spring highs after the U.S. and Iran reached an interim ceasefire agreement, offering some relief to airlines after a costly spring.
But the truce remains fragile.
Three tankers were struck by projectiles Tuesday in the Strait of Hormuz, according to the British military, and the U.S. revoked a license that had allowed Iranian oil sales under the agreement.
Delta Air Lines is set to report its second-quarter financial results on Friday, kicking off a wave of earnings reports from U.S. carriers.
Executives are expected to discuss how recent declines in fuel prices could affect the industry’s finances going forward.
The average price for a gallon of jet fuel was $2.88 across the key airline hubs of Chicago, Houston, Los Angeles and New York on Tuesday, according to the Argus U.S. Jet Fuel Index.
The price fell under $3 a gallon June 15 for the first time since early March and has remained below since.
Dhivya Suryadevara resigned as president of Fiserv on Tuesday (July 7), the company said in a filing with the Securities and Exchange Commission (SEC).
Suryadevara resigned for “good reason” under her offer letter, her resignation is effective Tuesday, and she will remain a non-executive officer employee through July 31 to enable an orderly transition of her duties, according to the filing.
According to the offer letter dated Aug. 28, 2025, and included in Fiserv’s Annual Report on Form 10-K for the year ended Dec. 31, 2025, “good reason” events include a material reduction in base salary or annual incentive compensation target, a material adverse change to duties or responsibilities, or a change to the company’s CEO.
Fiserv announced June 15 that Mike Lyons stepped down as CEO and member of the board of directors to become CEO of Truist. The company also said it appointed Takis Georgakopoulos, who was its co-president leading Technology and Merchant Solutions, as CEO and as a member of the board of directors, effective June 15.
About eight months earlier, the company announced in an October press release that Georgakopoulos and Suryadevara would serve as co-presidents, effective Dec. 1, 2025, with Suryadevara serving as the head of Financial Solutions, Sales and Operations.
Suryadevara joined Fiserv at that time. Immediately prior to that, Suryadevara served as CEO of Optum Financial and Optum Insight at UnitedHealth Group.
When Suryadevara discussed artificial intelligence and banks with PYMNTS CEO Karen Webster in June, PYMNTS reported that Suryadevara also held senior leadership roles at Stripe and General Motors before joining UnitedHealth Group and then Fiserv.
Fiserv also announced in its Tuesday filing with the SEC that it appointed Andrew Gelb and Srini Krish as interim leaders of the company’s Financial Solutions business, effective immediately.
Gelb joined Fiserv in 2014 and is the company’s executive vice president and chief operating officer, Financial Solutions. Krish joined Fiserv in 2014 and is the company’s head of technology and operations, Financial Solutions.
When announcing Lyons’ departure in a June 15 press release, Fiserv said that it reaffirmed the outlook for the full year 2026 that it provided on May 5. The outlook called for organic revenue growth of 1% to 3% and adjusted earnings per share of $8 to $8.30 for 2026.
The June 12 initial public offering of Space Exploration Technologies (SPCX 6.83%), better known as SpaceX, shattered the record for the largest Wall Street IPO in history. That was only the beginning of a whirlwind of events for Elon Musk's business.
Just days later, on June 16, SpaceX announced its acquisition of artificial intelligence start-up Cursor for a whopping $60 billion. Then on June 22, the company issued its first bonds, selling $25 billion worth of debt.
These activities illustrate the broader trends occurring across the technology sector. Get ready for a wild ride ahead as tech companies maneuver for dominance in the rapidly evolving artificial intelligence landscape.
Image source: Getty Images.
SpaceX demonstrates the mounting price for AI The race is on for leadership positions in the artificial intelligence era. Achieving one will be no small task, as SpaceX's recent moves indicate.
Its acquisition of Cursor demonstrates that it recognizes the importance of creating a robust AI platform -- but it also shows the high costs involved. Cursor is a software development solution built on artificial intelligence that allows users to significantly accelerate programming tasks. It's proven popular, producing over $1 billion in annualized sales last year.
SpaceX is far from alone here. Others in the tech space are rushing to snatch up AI businesses. On June 15, customer relationship management titan Salesforce announced it was spending $3.6 billion to acquire Fin, which provides an AI agent to answer customer inquiries.
Along with acquisitions, AI brings other expenses, particularly related to infrastructure. SpaceX's inaugural bond offering is part of the company's financial maneuverings to position it for the capital commitments to come.
Building and powering the vast server farms required to create and support increasingly sophisticated AI systems requires enormous levels of capital expenditures.
Today's Change
(
-6.83
%) $
-10.95
Current Price
$
149.47
The tech industry's costly AI pursuit Several businesses in the tech sector are facing the stark reality that AI infrastructure is expensive. Oracle, which provides cloud infrastructure for AI, warned, "We must incur significant capital and operating expenditures to increase our existing data center capacity." To fund its AI infrastructure build-out, Google parent Alphabet recently announced a massive $84.75 billion equity capital raise.
Tech giant Meta Platforms increased its 2026 capital expenditure projection to a range between $125 billion and $145 billion. Last year, its capex to boost its AI capabilities was $72 billion. Wall Street was taken aback by this year's prodigious spending plan, and sold off Meta shares in response. The stock was down by nearly 20% over the past 12 months through July 2.
Accelerating AI costs are hitting many tech companies, even those that aren't directly investing in infrastructure. This year, Uber blew through its annual AI budget in four months, and management is questioning whether the outcomes are worth the expense.
Uber's sentiment extended to Wall Street, where concerns over rapidly rising AI costs led to a tech sector sell-off in June. SpaceX shares, which soared to $225.64 post-IPO, crashed to $147.11 on June 23.
Until clarity emerges on whether all the AI spending is worth it, volatility is likely to persist across the technology sector. While it does, remember that the smart strategy is to keep a cool head and focus on the long-term performance of the tech companies in your portfolio, not their short-term stock oscillations.
Robert Izquierdo has positions in Alphabet, Meta Platforms, Oracle, Salesforce, and Uber Technologies. The Motley Fool has positions in and recommends Alphabet, Meta Platforms, Oracle, Salesforce, and Uber Technologies. The Motley Fool has a disclosure policy.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of META either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Netflix (NFLX +0.31%) reports second-quarter results on July 16, and it does so from an unusual spot: the business keeps growing, yet the stock has been sliding for a year. Shares trade around $76 as of this writing, down about 42% from the high of $130.23 they set last summer -- even as revenue, profits, and the company's nascent advertising arm all keep climbing. With the report just over a week away, is this a good time to buy the stock?
Let me walk through what the quarter needs to show, and whether the discounted price is worth the risk of another slide.
Image source: The Motley Fool.
A business that keeps growing Netflix's problem, if you can call it that, isn't the business. In the first quarter of 2026, revenue rose 16% year over year to $12.25 billion, helped by membership growth, a price increase, and a fast-growing advertising business. Its operating margin, meanwhile, widened to 32.3% from 31.7% in the same quarter a year ago. The company has stopped disclosing subscriber counts every quarter, but it topped 325 million paid memberships and is now entertaining an audience approaching 1 billion people.
The streaming service's advertising arm is the piece to watch. Netflix expects ad revenue to roughly double this year to around $3 billion, it now works with more than 4,000 advertisers, up about 70% from a year ago, and the ad-supported plan has become the most popular choice for new sign-ups in the countries where it is offered. For a company that long leaned almost entirely on subscription fees, that second engine matters, because it lets Netflix lift revenue per member without relying solely on price increases. For all of 2026, management is guiding for revenue between $50.7 billion and $51.7 billion -- a 12% to 14% increase -- with an operating margin near 31.5%.
If results are this solid, why has the stock lost 42%? Two reasons. First, Netflix came into 2025 with expectations set impossibly high, and once its guidance stopped clearing an ever-rising bar, that premium began to unwind. Second, the company spent months tangled in a takeover fight. Netflix had agreed to acquire the Warner Bros. studios and HBO Max from Warner Bros. Discovery in a deal with an equity value around $72 billion, which drew a rival bid and a stretch of uncertainty -- before Netflix ultimately walked away and turned to share buybacks instead.
With that distraction behind it, the story is simpler now: a steadily growing business trading well off its highs.
Today's Change
(
0.31
%) $
0.24
Current Price
$
76.26
Buy before the report? Valuation is where the decision gets interesting. After the slide, Netflix trades at about 25 times earnings and around 23 times the earnings expected over the coming year. For a company still growing revenue in the mid-teens, expanding margins, and doubling its advertising business, that is a far more reasonable price than the stock commanded at its peak.
It is worth appreciating how far the stock has already de-rated. A year ago, Netflix carried one of the richest multiples in big-cap tech. Today it trades at a fraction of its former multiple, even though it is still growing faster than most of its large-cap peers. The company is also throwing off record free cash flow and using part of it to buy back stock, which quietly lifts per-share earnings. None of that guarantees the shares have bottomed, but it does mean today's buyers are paying a far more grounded price than they were 12 months ago.
Of course, there are risks. Streaming is fiercely competitive, and Netflix has to keep spending heavily on content to hold its lead against deep-pocketed rivals. In addition, there are risks associated with buying before July 16. Buying right before an earnings report is a bet on the outcome of a single day. If subscriber trends or another key metric, like revenue growth, disappoints, shares could take a hit -- reasonable valuation or not.
So, is Netflix a buy before the report? For long-term investors, I think the stock is finally priced attractively enough to start a position -- but not to try to make a quick buck from a potential bounce when the earnings report is released. Shares could just as easily fall. If you like Netflix for its long-term potential, though, this looks like a reasonable entry point.
SummaryZoom Communications is upgraded to Strong Buy, driven by robust financials, expanding AI initiatives, and an undervalued Anthropic stake as its potential IPO approaches.Q1 FY27 saw 5.5% revenue growth, a 40.4% FCF margin, and $1.56B in buybacks over 12 months, with another $1 billion buyback authorization announced recently.ZM's balance sheet remains a fortress with $7.72B in net cash, supporting continued innovation, investments, and international expansion.Valuation implies a solid margin of safety, with DCF-derived fair value at $94.21/share, excluding potential Anthropic IPO upside. 10'000 Hours/DigitalVision via Getty Images
Introduction The first time I covered Zoom Communications (ZM), highlighting the company's exceptional financial position and significant expansion potential into a diversified work platform, as well as a small Anthropic (
3.19K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ZM over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
PepsiCo (PEP) is scheduled to report Q2 2026 results before the market opens on Thursday, July 9, kicking off the earnings season for many consumer staples companies.
Oracle (ORCL 1.56%) was founded as a software company in 1977, before transitioning first to cloud computing and later to artificial intelligence (AI) infrastructure. It operates some of the fastest and most cost-efficient AI data centers in the world, and its order backlog suggests demand is through the roof.
Nevertheless, Oracle stock plummeted by 25% during the first half of 2026, and it's down by more than 50% from last year's record high. Wall Street is concerned that some of Oracle's largest AI customers won't be able to fulfill their obligations, which would be catastrophic because the company has taken on an enormous amount of debt to build more data centers.
Those concerns reached a crescendo on June 10, when Oracle released its annual report for fiscal 2026 (ended May 31). It contained some unusual and very thorough warnings about the risks facing its AI infrastructure business, and here's why I think they give investors enough reason to avoid its stock.
Image source: The Motley Fool.
Oracle operates some of the best AI data centers AI training and inference workloads require a lot of computing capacity, which is typically delivered by thousands of specialized data center chips called graphics processing units (GPUs). Oracle buys these chips from some of the world's top suppliers, like Nvidia and Advanced Micro Devices, installs them in its infrastructure, and rents the computing capacity to other businesses.
Oracle has a couple of advantages over other cloud companies. First, it uses a high degree of software-powered automation to run its data centers, which means it can bring new infrastructure online much faster than operators that rely on human-led processes. Second, its random direct memory access (RDMA) networking technology moves data between chips and devices faster than traditional Ethernet networks.
These features result in lower costs and faster processing speeds, the perfect combination for AI developers, who typically pay for computing capacity by the minute. That's why top companies like OpenAI, Elon Musk's xAI, and Meta Platforms are lining up to use Oracle's infrastructure.
In fact, the company ended fiscal 2026 with a staggering $638 billion in remaining performance obligations (RPO) from customers waiting for more data centers to come online, a figure that had soared by 363% year over year. RPO reflects the value of signed contracts for services that haven't been delivered yet, so it's similar to an order backlog. Oracle says the $638 billion figure is a good reflection of future revenue, but its latest annual report is littered with warnings to the contrary.
Almost half of Oracle's RPO is reportedly from one customer According to a report by The Wall Street Journal from last September, around $300 billion of Oracle's RPO is attributable to OpenAI alone, and that poses a few problems. First, OpenAI has just $25 billion in annualized revenue. Second, it's losing money, so it relies on funding from outside investors to cover its operations -- in fact, it recently raised a whopping $122 billion in fresh capital.
Third, OpenAI has made commitments on a similar scale to other cloud providers like Microsoft, so the start-up is hundreds of billions of dollars short of being able to fulfill all its obligations. That might explain why Oracle provided the following warning in its fiscal 2026 annual report:
Some of our customers may be highly leveraged and subject to their own operating and regulatory risks and, even if our credit review and analysis mechanisms work properly, we may experience risks of non-payment and non-performance in our dealings with such parties. In certain OCI offerings, we are more concentrated among a number of large customers, which could increase these risks.
Oracle also warned that it could be overestimating customer demand and that it might be unable to release its AI data center capacity to other parties or repurpose it for other workloads. In other words, Oracle could wind up sitting on a ton of infrastructure it simply can't use.
Today's Change
(
-1.56
%) $
-2.24
Current Price
$
141.52
Oracle expects to convert only around 12% of its total RPO into revenue over the next 12 months, followed by a further 34% in the 24 months after that. In simpler terms, less than half of its RPO will become revenue over the next three years in the best-case scenario. A lot can change in that time, especially in an industry moving as quickly as AI. There is a real risk that many of Oracle's customers won't need all the computing capacity they have signed up for.
This could have dire consequences for the company, as it's carrying over $122 billion in long-term debt and recently announced plans to raise another $40 billion through a mix of debt and equity to fund more data centers. Therefore, I'm not surprised investors are heading for the exits -- I certainly won't be buying this stock as things currently stand.
UPS remains a 'sell' as top-line recovery could be postponed, while dividend sustainability is in question. Amazon's move to open its logistics network to third parties intensifies competition, directly threatening UPS's growth and margin outlook. Despite aggressive cost cuts and a higher-margin focus, FCF remains insufficient to cover the $1.64 dividend, raising the risk of a cut.
New York, New York--(Newsfile Corp. - July 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
SO WHAT: If you purchased Zillow common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304285
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
The White House South Lawn is under construction to accommodate a permanent presidential helipad for Marine One landings. Al Drago/The Washington Post via Getty Images The White House is getting a permanent helipad installed on the South Lawn.
President Donald Trump confirmed to reporters in the Oval Office on Monday that the White House is getting a granite helipad paid for by Sikorsky Aircraft — a subsidiary of Lockheed Martin — to support the new fleet of helicopters used as Marine One.
A Lockheed Martin spokesperson confirmed the contribution and told Business Insider it was being made to the National Park Service.
Trump said the permanent fixture will help protect the South Lawn's grass.
The newer helicopters from Sikorsky are about "two and a half times more powerful than the old ones," Trump said.
"When you land on the grass, it's not that the grass gets discolored. It gets ripped out," he said.
Trump told reporters that the helipad will bear the White House seal and that Sikorsky will pay for the project. The president said the helipad will cost between $5 million and $6 million.
"Sikorsky is paying for it. You know why? Because they didn't tell us how powerful these helicopters were," Trump said. "And they felt a little bit guilty."
A Sikorsky spokesperson said that the new model for presidential transport — the VH-92A Patriot — delivers "increased performance and reduced maintenance costs and time over the current fleet of presidential helicopters."
Spokespeople for Sikorsky and Lockheed did not say how much the project would cost or how long construction would take.
A White House spokesperson did not respond to a request for comment.
Recent photos show that the helipad is under construction.
Using the South Lawn as a landing area for transporting the commander in chief dates back to the Eisenhower administration, as helicopters provided a faster, easier mode of transport without the need for a motorcade.
In lieu of a traditional landing pad, Marine One typically lands on temporary landing plates or circular disks placed on the lawn.
Below are photos documenting the history of helicopter landings at the White House and the installation of the new helipad.
Aviation pioneer James Ray landed an autogyro, an aircraft with a spinning rotor on top, on the White House South Lawn for the first time in 1931.
James Ray landing an autogyro aircraft on the White House South Lawn. Library of Congress/Interim Archives/Getty Images James Ray parked a Pitcairn-Cierva PCA-2 autogyro on the South Lawn as part of an award ceremony, according to the National Air and Space Museum. It was the first recorded instance of a rotary-wing aircraft landing on the lawn.
In 1957, President Dwight D. Eisenhower became the first US president to use helicopter transport from the White House lawn.
President Dwight D. Eisenhower is about to board a helicopter from the White House South Lawn. Universal History Archive/Universal History Archive/Universal Images Group via Getty Images The first documented instance of Eisenhower boarding a helicopter from the South Lawn was on July 12, 1957, according to The History Channel.
The Marine Corps website states that helicopter transport helped turn a two-hour motorcade into a seven-minute helicopter ride.
Helicopter transport for the US president to and from the White House South Lawn later became standard operating procedure for short-distance travel.
President Richard Nixon gives his iconic "V" sign as he departs from the White House South Lawn after resigning the presidency. Bettmann/Bettmann Archive The White House helicopter transport was named Marine One, a call sign for a Marine Corps aircraft carrying the president.
The fleet is operated by Marine Helicopter Squadron One, known as HMX-1 or the Nighthawks.
Marine One has become one of the most visible symbols of presidential travel, next to Air Force One.
Instead of a permanent helipad, White House personnel would place large landing disks on the South Lawn for Marine One helicopters.
White House personnel place landing targets on the South Lawn of the White House Nicholas Kamm/AFP via Getty Images The landing targets provide the aircraft with a stable contact point and could reduce turf damage.
The South Lawn is no match for the new Sikorsky aircraft.
Sikorsky VH-92A Patriot replaced the older fleet of helicopters for Marine One. Craig Hudson/Reuters In 2024, Lockheed Martin's Sikorsky formally delivered the VH-92A helicopter to the US Marine Corps to replace the older fleet of aircraft used for Marine One.
The government spent $5 billion on the new fleet.
Bloomberg previously reported in 2024 that issues with the VH-92A scorching the South Lawn have delayed the aircraft's ability to transport the president.
Trump says construction of the presidential helipad is underway.
A helipad is under construction on the White House South Lawn Win McNamee/Getty Images Photos show that the grass on the South Lawn has been removed to make way for the construction of the permanent granite helipad.
"For 50 years, we've been landing helicopters on grass," Trump told reporters on Monday. "The grass is wet, soggy."
The helipad is only one of the construction projects the White House is going through under Trump 2.0.
A helipad is under construction on the White House South Lawn Kevin Carter/Getty Images Other renovation projects pursued under the second Trump administration include the demolition of the East Wing to make room for a 90,000 square-foot White House ballroom.
The project is estimated to cost $400 million.
The administration also hosted a UFC fight at the White House in June, temporarily turning the South Lawn into an arena.
Read next
Lloyd Lee You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
An analyst's recommendation downgrade didn't do any favors for Broadcom (AVGO 0.83%) stock on Tuesday. That, plus the latest news of a company developing a proprietary artificial intelligence (AI) chip, pushed Broadcom's equity down by almost 1% that trading session.
Tapping the brakes on Broadcom The downgrading party was Austrian bank Erste Group. That morning, its analyst Hans Engel moved his Broadcom recommendation down one peg to hold from buy. It was unclear what price target the pundit set.
Image source: Getty Images.
While Engel waxed bullish on the company's prospects as a developer and maker of next-generation custom AI chips, according to reports, he expressed concern about its valuations.
These are somewhat immodest at the moment, with, for example, a price/sales ratio over 23. Engel wrote that given such multiples, the stock's upside could be limited even if it posts impressive growth like it has in the past.
Broadcom's stock was also affected by a Reuters report stating that DeepSeek, a high-profile AI developer based in China, had launched a project to make its own AI chip. This is part of a recent trend of companies independently developing such goods, in an attempt to reduce dependence on third-party "chippies" like Broadcom.
Today's Change
(
-0.83
%) $
-3.12
Current Price
$
370.78
The potential proprietary threat Of the two developments, I'd keep a sharper eye on that proprietary chip development trend. If it really snowballs in the coming months and years, Broadcom and its peers could face a serious challenge. As it is now, though, the thirst for quality AI hardware is unquenchable, and simply by virtue of this, Broadcom should continue to do well. I remain bullish on the company's future.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Broadcom. The Motley Fool has a disclosure policy.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the “Class Period”), of the important August 7, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Roblox common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Roblox’s organic growth potential; notably, that Roblox would see a significant slowdown in its growth rates as enrollment in the age verification rollout would quickly taper, compounding the resulting slowdown in on-platform communication, resulting in app store rating reductions and a swift reduction in organic growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
, /PRNewswire/ -- National shareholder rights firm Hagens Berman is investigating claims alleged in a pending securities class action suit against Roblox Corporation (NYSE: RBLX) and its management following disclosures that the company's age verification rollout caused significant, undisclosed friction to its user growth and platform engagement.
SUBMIT YOUR RBLX LOSSES TO HBSS NOW
The firm's investigation focuses on the suit's claims that Defendants misled investors regarding the operational consequences of the safety-focused initiatives the company had purportedly implemented.
Allegations Concerning Age Verification and Growth:
The suit follows a sharp decline in Roblox's share price on May 1, 2026, after the company reported its Q1 2026 financial results. The core allegations, which have emerged in recently filed complaint against the company, contend that Roblox failed to disclose that its age-check rollout:
Reduced Platform Engagement: The age verification features hindered on-platform communication, leading to a decline in user interaction. Negatively Impacted Organic Growth: The friction caused by these features resulted in lower app store ratings and a corresponding reduction in organic user sign-ups. Misrepresented Growth Potential: Throughout the class period (October 30, 2025 – April 30, 2026), Roblox characterized the rollout as a "gold standard" implementation while allegedly knowing it would lead to a significant slowdown in user growth. Key Disclosures and Market Impact
April 30, 2026: Roblox revealed a steep deceleration in year-over-year and sequential DAU growth, slashed its 2026 revenue guidance and severely cut its 2026 bookings growth. The company blamed its dismal results on just 51% of Roblox global DAUs having age checked. The company further revealed that "as a result of age check […] we have seen a reduction in app store ratings, and we believe this may be contributing to a reduction in organic sign-ups that typically flow from app stores." Roblox also said its lowered prospects are the result of "continued friction" resulting from the age-check rollout. Market Correction: The news caused Roblox shares to fall $10.13, or approximately 18.33%, on May 1, 2026, erasing over $6.7 billion in market capitalization. Hagens Berman's Investigation
"We're focused on when Roblox and its management knew of the adverse consequences of the age-check rollout and whether they intentionally misled investors about it," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
Investor Rights and Lead Plaintiff Deadline
Hagens Berman is currently evaluating the claims alleged in the suit brought on behalf of a putative class of investors who purchased Roblox securities between October 30, 2025, and April 30, 2026. If you suffered financial losses on RBLX during the class period, you are encouraged to contact our office to learn more about your legal rights and the ongoing class action litigation. The court-imposed deadline to move for appointment as lead plaintiff is August 7, 2026.
Report your losses now Contact Our Attorneys: [email protected] Investor Hotline: 844-916-0895 Hagens Berman's Roblox Page: www.hbsslaw.com/cases/roblox If you'd like more information and answers to other frequently asked questions about the Roblox case and the firm's investigation, read more.
Whistleblowers: Persons with non-public information regarding Roblox should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
New York, New York--(Newsfile Corp. - July 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the "Class Period"), of the important August 7, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Roblox common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Roblox's organic growth potential; notably, that Roblox would see a significant slowdown in its growth rates as enrollment in the age verification rollout would quickly taper, compounding the resulting slowdown in on-platform communication, resulting in app store rating reductions and a swift reduction in organic growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304320
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
@cointelegraph's Ray Salmond remains bullish on Bitcoin, which saw a short-term uptrend even after Strategy (MSTR) sold $216 million worth of the cryptocurrency. Ray adds his thoughts on what the Fed's impact on cryptocurrencies looks like, noting that Bitcoin could be “on pins and needles tomorrow.
The spice aisle will no longer determine McCormick's (MKC +0.85%) fate. In March, the 137-year-old company announced an agreement to merge with Unilever's (UL +1.88%) food division, a business 1.5 times its size, in a $45 billion transaction.
The deal adds established brands like Hellmann's mayonnaise and Knorr bouillon to McCormick's portfolio, alongside household favorites like French's mustard and Frank's RedHot sauce.
The addition of Unilever Foods is an attempt to address the structural weakness that has weighed on the stock over the past few years. The complex nature of the transaction has done little to win over investors.
Image source: Getty Images.
A strategic shift away from seasonings The stock has been under pressure from the growth of private-label brands. In its core spice and seasoning category, store brands now command nearly 40% of unit volume, one of the highest penetrations in any grocery aisle.
This has eroded the company's pricing power and contributed to its recent underperformance. The merger is designed to dilute the effect of this challenged category.
Post-merger, the spice business will shrink from over 30% of total sales to less than 15%. In its place, McCormick adds categories like mayonnaise and bouillon, which face less private-label competition due to strong brand loyalty and taste differentiation.
The combined company will be larger, more diversified, and more profitable, with operating margins projected to expand from 17% to 21% post-integration. Yet, some investors see a complex transaction that dilutes current shareholders, adds significant debt, and creates a year-long overhang.
Integration will take time The transaction is structured as a Reverse Morris Trust, which complicates matters for shareholders of both companies. Existing McCormick shareholders will be heavily diluted, while debt on the balance sheet will increase to 4 times net debt-to-earnings before interest, taxes, depreciation, and amortization (EBITDA).
Meanwhile, Unilever shareholders may create selling pressure on the stock after receiving their MKC shares.
Today's Change
(
0.85
%) $
0.44
Current Price
$
52.22
The strategic rationale for reducing spice exposure is sound, but the execution risks create uncertainty. The merger is not expected to close until mid-2027 at the earliest, creating an extended overhang.
Currently, with inflation driving shoppers to cheaper alternatives, there's no reason to rush into the stock. As the dust settles on the deal and we get a better sense of the company's integration plans and cost structure, the stock could be worth a closer look.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ZoomInfo To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in ZoomInfo between November 3, 2025 and May 11, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - July 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ZoomInfo Technologies, Inc. ("ZoomInfo" or the "Company") (NASDAQ: GTM) and reminds investors of the August 24, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of ZoomInfo's slowing growth its legacy seat-based subscription platforms and weakening customer retention in its downmarket segment. Further, the Company minimized concerns that customers were moving towards consumption-based usage models and developing internal AI-driven go-to-market solutions.
On May 11, 2026, after the market closed, ZoomInfo announced its first quarter 2026 financial results, unveiling a sharp decline in growth outlook and accordingly lowered its 2026 full year financial guidance, and announced it was realigning its downmarket business, laying off 20% of its workforce, and expecting to incur approximately $45-60 million in restructuring costs. On this news, ZoomInfo's stock price fell $1.98, or approximately 33%, to close at $4.06 per share on May 12, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding ZoomInfo's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the ZoomInfo class action, go to www.faruqilaw.com/GTM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the ZoomInfo Securities Class Action Lawsuit:
What is the ZoomInfo securities fraud lawsuit about?
The lawsuit alleges that ZoomInfo Technologies, Inc. (NASDAQ: GTM) and certain of its officers and directors violated federal securities laws by making materially false and misleading statements to investors during the class period. Specifically, the complaint alleges that defendants issued overwhelmingly positive statements while allegedly concealing the true extent of slowing growth in ZoomInfo's legacy seat-based subscription platforms and weakening customer retention in its downmarket segment. The complaint further alleges that defendants minimized concerns that customers were shifting toward consumption-based usage models and developing internal AI-driven go-to-market solutions, which allegedly masked material adverse trends affecting the Company's business. On May 11, 2026, after markets closed, ZoomInfo allegedly disclosed the severity of these conditions when it announced sharply lowered full-year 2026 guidance, a realignment of its downmarket business, a workforce reduction of approximately 20%, and anticipated restructuring costs of approximately $45-60 million - news that allegedly caused the Company's stock to decline approximately 33% the following trading day.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired ZoomInfo Technologies, Inc. (NASDAQ: GTM) securities during the class period - between November 3, 2025 and May 11, 2026, inclusive - may be eligible to participate in this lawsuit. Eligible investors are not limited to those who seek appointment as lead plaintiff; any class member who suffered losses during the class period may potentially share in any recovery obtained on behalf of the class. Investors are encouraged to review their trading records to determine whether their purchases fall within the applicable class period dates. Participation in the litigation does not require that an investor take an active role in the case or incur out-of-pocket legal expenses to be considered a potential class member.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including selecting and overseeing class counsel and making key strategic decisions in the case. Under the Private Securities Litigation Reform Act, any investor who purchased ZoomInfo Technologies securities during the class period and suffered a loss may move the court for appointment as lead plaintiff. The deadline to file a motion seeking lead plaintiff appointment is August 24, 2026. Importantly, investors are not required to serve as lead plaintiff in order to be eligible to share in any recovery that may result from the litigation; the vast majority of class members participate without taking on that representative role.
What should investors do if they purchased ZoomInfo stock during the Class Period?
Investors who purchased ZoomInfo Technologies, Inc. (NASDAQ: GTM) securities between November 3, 2025 and May 11, 2026 should promptly review their brokerage and account records to confirm the dates and prices of any relevant transactions. Investors are strongly encouraged to preserve all documentation related to their ZoomInfo securities purchases, including trade confirmations, account statements, and any communications concerning those investments. Given that the lead plaintiff motion deadline is August 24, 2026, investors who wish to explore their legal options - including the possibility of seeking appointment as lead plaintiff - should act in a timely manner. Investors may wish to consult with Faruqi & Faruqi, LLP or other qualified securities counsel to evaluate their rights and potential claims prior to that deadline.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased ZoomInfo securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304092
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Ross Stores (ROST - Free Report) closed the most recent trading day at $214.67, moving +1.57% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.45%. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, lost 1.16%.
Heading into today, shares of the discount retailer had lost 7.06% over the past month, lagging the Retail-Wholesale sector's loss of 0.18% and the S&P 500's gain of 2.14%.
Market participants will be closely following the financial results of Ross Stores in its upcoming release. The company is predicted to post an EPS of $1.9, indicating a 21.79% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $6.1 billion, indicating a 10.36% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $7.74 per share and revenue of $24.81 billion. These totals would mark changes of +17.1% and +9.06%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Ross Stores. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Right now, Ross Stores possesses a Zacks Rank of #1 (Strong Buy).
Investors should also note Ross Stores's current valuation metrics, including its Forward P/E ratio of 27.32. This valuation marks a premium compared to its industry average Forward P/E of 26.68.
One should further note that ROST currently holds a PEG ratio of 2.37. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Retail - Discount Stores was holding an average PEG ratio of 2.37 at yesterday's closing price.
The Retail - Discount Stores industry is part of the Retail-Wholesale sector. With its current Zacks Industry Rank of 25, this industry ranks in the top 11% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Item 1 of 2 Attorney General of Oregon Dan Rayfield looks on outside the U.S. Supreme Court in Washington, D.C., U.S., November 5, 2025. REUTERS/Nathan Howard
[1/2]Attorney General of Oregon Dan Rayfield looks on outside the U.S. Supreme Court in Washington, D.C., U.S., November 5, 2025. REUTERS/Nathan Howard Purchase Licensing Rights, opens new tab
SummaryCompaniesParamount expected to close deal on or before July 16Oregon wants records of Paramount lobbying effortCalifornia, New York also probing dealJuly 7 (Reuters) - The Oregon attorney general will ask a court to order Paramount (PSKY.O), opens new tab to comply with investigative demands related to its $110 billion bid to acquire Warner Bros (WBD.O), opens new tab, according to documents reviewed by Reuters.
Paramount intends to close the deal on or immediately after July 16, the state said in documents to be filed in court. Oregon Attorney General Dan Rayfield will seek an expedited hearing on the matter, or an order that would prevent the deal from closing until a hearing can be held, according to the documents.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
"The information the Oregon Department of Justice is seeking has nothing to do with whether this transaction complies with Oregon’s antitrust laws and is not a legitimate basis to delay a plainly lawful, pro-competitive transaction," a Paramount spokesperson said on Tuesday.
The company has provided the state with documents relevant to the merger, the spokesperson added.
The company has said the deal would create a stronger streaming competitor to Netflix (NFLX.O), opens new tab and Disney (DIS.N), opens new tab, and benefit creatives and consumers.
California, New York and other U.S. states are preparing to sue to block the deal, sources familiar with the matter told Reuters last month. The states have authority to enforce laws against mergers that they believe would unlawfully decrease competition.
Opponents of the deal, including some actors, writers and media workers, have worried that it would hurt jobs.
Oregon is seeking documents regarding "Project Warrior," which was Paramount's internal code name for efforts to obtain regulatory clearance. The state is also asking for records related to the company's efforts to lobby the Trump administration for support of the merger.
Paramount CEO David Ellison's father, billionaire Oracle co-founder Larry Ellison, has cultivated ties with President Donald Trump, and the company has hired former Trump officials.
The state wants the documents in order to evaluate the U.S. Department of Justice's clearance of the deal, according to the documents.
While Oregon ordinarily "would afford significant weight" to the DOJ's determination, the state cited a Wall Street Journal report that officials overrode career staff attorneys at the DOJ who were leaning towards a recommendation to challenge the deal.
The DOJ issued a lengthy statement last month saying it believed the deal would "increase competition across the media and entertainment ecosystem, with benefits for American consumers and workers."
Reporting by Jody Godoy in New York and Dawn Chmielewski in Los Angeles; Editing by Tom Hogue and Sonali Paul
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Jody Godoy reports on tech policy and antitrust enforcement, including how regulators are responding to the rise of AI. Reach her at [email protected]
Shares of Rivian Automotive (RIVN 18.12%) reversed course on Tuesday after the electric vehicle (EV) manufacturer announced a sizable capital raise.
Image source: Getty Images.
Deliveries are rising, but so are production costs On Thursday, Rivian announced that it delivered 12,194 vehicles in the second quarter, handily exceeding its guidance of 9,000 to 11,000 deliveries. Strong sales of the company's pickup trucks and delivery vans contributed to the outperformance.
The results prompted the automaker to boost its full-year deliveries goal to 65,000 to 70,000, up from a prior forecast of 62,000 to 67,000.
Unsurprisingly, the news drove investors to bid up the EV maker's shares.
Today's Change
(
-18.12
%) $
-3.65
Current Price
$
16.49
Yesterday, however, Rivian said it would sell 75 million shares of its stock to raise cash. The company also granted underwriters a 30-day option to purchase an additional 11.25 million shares.
Based on current prices, the share offering could raise more than $1.4 billion. Rivian plans to use the proceeds to fund its growth initiatives and equity contributions related to a loan from the U.S. Department of Energy.
Disdain for dilution drove investors to sell Rivian's share sale reminded investors that it's still a long way from achieving sustained profitability. And even when the EV upstart performs well, as it did when it raised its full-year vehicle delivery target on July 2, the good news is often followed by stock offerings that can halt and even reverse its share price gains.
That can be frustrating for all but the most patient investors. Many shareholders, in turn, decided to sell today.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
McKesson (MCK - Free Report) ended the recent trading session at $807.33, demonstrating a +2.95% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 0.45%. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq lost 1.16%.
The prescription drug distributor's shares have seen an increase of 2.29% over the last month, not keeping up with the Medical sector's gain of 6.33% and outstripping the S&P 500's gain of 2.14%.
The upcoming earnings release of McKesson will be of great interest to investors. The company's earnings report is expected on August 5, 2026. In that report, analysts expect McKesson to post earnings of $9.63 per share. This would mark year-over-year growth of 16.59%. Alongside, our most recent consensus estimate is anticipating revenue of $104.39 billion, indicating a 6.7% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $44.28 per share and a revenue of $432.83 billion, signifying shifts of +13.22% and +7.29%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for McKesson. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0% higher. Currently, McKesson is carrying a Zacks Rank of #3 (Hold).
Digging into valuation, McKesson currently has a Forward P/E ratio of 17.71. This valuation marks a premium compared to its industry average Forward P/E of 17.08.
It's also important to note that MCK currently trades at a PEG ratio of 1.29. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Dental Supplies was holding an average PEG ratio of 1.9 at yesterday's closing price.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 32% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
, /PRNewswire/ -- Hub Group, Inc. (NASDAQ: HUBG) and certain of its current and former executives (together, "co-defendants") face a securities class action lawsuit, which seeks to represent investors who purchased or acquired Hub Group securities between April 28, 2023 and May 11, 2026.
The development follows the company's surprise revelations that its financial reports going back to 2023 were "materially misstated and should no longer be relied upon" and corrective actions taken against two senior executives.
National shareholder rights firm Hagens Berman continues to investigate legal claims that Hub Group and its co-defendants violated the federal securities laws and urges investors who suffered significant losses to submit your losses now.
Class Period: Apr. 28, 2023 – May 11, 2026
Lead Plaintiff Deadline: Aug. 28, 2026
Visit: www.hbsslaw.com/investor-fraud/hubg
Contact the Firm Now: [email protected]
844-916-0895
Hub Group, Inc. (HUBG) Securities Class Action:
The lawsuit focuses on the propriety of Hub Group's repeated assurances that its financial statements were prepared in conformity with applicable accounting rules.
Contrary to these assurances, the complaint alleges that throughout the Class Period the co-defendants made false and misleading statements concerning Hub Group's premature and incorrect revenue recognition and understatement of purchased transportation costs and accounts payable.
Investors learned the truth through a series of Hub Group's partial disclosures about its accounting and ramifications for certain of its executives.
First, on February 6, 2026, investors saw the price of their Hub Group shares crater $9.37 (-18%) after the company (while touting that "[a]ccuracy and transparency in reporting on our performance is of utmost importance[]") revealed that during the first nine months of 2025 it had understated purchased transportation costs and accounts receivable by $77 million. Accordingly, the company said investors should not rely on its Q1 – Q3 2025 financial statements and it plans to restate them.
Second, on May 12, Hub Group shares tumbled again – this time, shares fell $5.24 (-12.5%) – on new disclosures much worse than on February 6. The company said its financial statements for the years ended December 31, 2023 and 2024 were materially misstated and that investors should no longer rely on those either. Hub Group explained only that it "identified certain transactions that were prematurely or incorrectly recognized or not adequately supported[]" and cautioned it was continuing to review "additional accounting issues that may potentially further impact" the 2023 and 2024 financial statements.
Between February 5, 2026 (the day before Hub Group's first partial corrective disclosure) and May 12, 2026, shareholders have seen over $890 million of Hub Group's market capitalization wiped out.
After the Class Period, on June 2, 2026, Hub Group announced that Chief Financial Officer Kevin Beth and Chief Operating Officer Brian Meents both left the company on May 27. The company said the executive departures were part of its corrective actions related to its financial statement review.
"Now that Hub Group has almost cleaned out its C-suite following accounting improprieties reaching all the way back to 2023, the core focus of our investigation is whether they were intentional or reckless with the goal of making financial metrics appear better than they actually were. We're also looking to see whether additional problems will surface when the company's review is completed," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in Hub Group and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »
If you'd like more information and answers to other frequently asked questions about the Hub Group case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding Hub Group should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026.
So what: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Insulet Corporation class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
GREEN BAY, Wis.--(BUSINESS WIRE)--Schneider (NYSE: SNDR), a premier multimodal provider of transportation, intermodal and logistics services, today announced it will report its second quarter 2026 results after market close on Thursday, July 30, 2026. The Company will hold a conference call to discuss results at 4:30 p.m. Eastern Time that day. Conference call details: Date: July 30, 2026 Time: 4:30 p.m. ET Dial-In-Numbers: 833-461-5787 (toll-free) 585-542-9983 Conference ID: 851962867 The Comp.
, /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, alerts investors in Commvault Systems, Inc. (NASDAQ: CVLT) that a newly filed securities class action lawsuit has expanded the alleged class period. The lawsuit now covers investors who purchased or otherwise acquired Commvault securities between January 28, 2025, and January 26, 2026, inclusive.
Hagens Berman is investigating the claims pled in the pending litigation and encourages Commvault investors who suffered substantial losses to submit your losses now.
Expanded Alleged Class Period: Jan. 28, 2025 – Jan. 26, 2026
Lead Plaintiff Deadline: July 17, 2026
Visit: www.hbsslaw.com/investor-fraud/cvlt
Contact the Firm Now: [email protected]
844-916-0895
Expanded Scope of Allegations
The new suit, City of Fort Lauderdale Police and Firefighters' Retirement System v. Commvault Systems, Inc., et al., extends the start of the alleged fraud period from April 29, 2025, back to January 28, 2025. This expansion captures a broader range of investor activity and expands the claims brought against the company and its senior executives regarding their business disclosures.
Focus of CVLT Securities Class Action Litigation:
The litigation alleges that Defendants misrepresented and failed to disclose that:
Commvault's competitive positioning was materially weaker than Defendants had represented to investors; Due to the undisclosed increase in competition, Commvault was forced to make significant concessions on price and contract duration for its software licenses; As these concessions became unsustainable, SaaS became a larger portion of the Company's sales mix; The increasing mix of SaaS sales, which carry shorter term durations and lower ASPs, negatively impacted the Company's margin and NNARR; and As a result, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The truth allegedly emerged before markets opened on January 27, 2026, when Commvault announced its third-quarter fiscal year 20261 financial results. Commvault disclosed NNARR in constant currency of $39 million, missing analysts' expectations of approximately $45 million. Chief Accounting Officer Danielle Abrahamsen ("CAO Abrahamsen") revealed that the mix of SaaS deals increased to "70%" during the quarter and highlighted that "landing these customers at a 2 to 3x smaller ASP than software . . . does have a significant impact on ARR."
On this news, the price of Commvault common stock fell $40.23 per share, or about 31%, to close at a price of $89.13 per share on January 27, 2026.
HBSS Investigation
"We continue to investigate whether Commvault misled investors about its operational performance and financial reporting during the alleged expanded class period, as the new complaint contends" said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims.
If you invested in Commvault and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now.
If you'd like more information and answers to frequently asked questions about the Commvault case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding Commvault should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Vertex Pharmaceuticals (VRTX - Free Report) closed at $522.25 in the latest trading session, marking a -1.39% move from the prior day. This change lagged the S&P 500's daily loss of 0.45%. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq lost 1.16%.
The drugmaker's stock has climbed by 19.56% in the past month, exceeding the Medical sector's gain of 6.33% and the S&P 500's gain of 2.14%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company is forecasted to report an EPS of $4.79, showcasing a 5.97% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.22 billion, up 8.46% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $19.15 per share and revenue of $13.03 billion, which would represent changes of +4.08% and +8.57%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Vertex Pharmaceuticals presently features a Zacks Rank of #3 (Hold).
Looking at its valuation, Vertex Pharmaceuticals is holding a Forward P/E ratio of 27.66. For comparison, its industry has an average Forward P/E of 21.91, which means Vertex Pharmaceuticals is trading at a premium to the group.
It's also important to note that VRTX currently trades at a PEG ratio of 2.01. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.73 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 158, placing it within the bottom 36% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
In the latest trading session, IonQ, Inc. (IONQ - Free Report) closed at $45.36, marking a -7.18% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.45% for the day. Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw a decrease of 1.16%.
Prior to today's trading, shares of the company had lost 22.18% lagged the Computer and Technology sector's gain of 0.38% and the S&P 500's gain of 2.14%.
Market participants will be closely following the financial results of IonQ, Inc. in its upcoming release. It is anticipated that the company will report an EPS of -$0.29, marking a 58.57% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $66.36 million, indicating a 220.73% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.07 per share and a revenue of $267.45 million, representing changes of +41.21% and +105.71%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for IonQ, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. IonQ, Inc. presently features a Zacks Rank of #3 (Hold).
The Computer - Integrated Systems industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 5, finds itself in the top 3% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
, /PRNewswire/ -- Peabody Energy Corporation (NYSE: BTU) faces a securities class action lawsuit related to surprise disclosures the company made to investors on March 30 and May 5, 2026 about problems with its flagship metallurgical coal asset ("Centurion").
The lawsuit seeks to represent investors who purchased or otherwise acquired shares of Peabody common stock between October 14, 2024 and May 4, 2026.
Between March 27 (the trading day before the first cryptic disclosure) and the May 5, 2026 fuller disclosure, investors saw the price of Peabody shares crumble $14.50 (-36%). Accordingly, the severe market reactions upon the company's revelations support national shareholder rights firm Hagens Berman's investigation into legal claims that Peabody and its co-defendants violated the federal securities laws.
The firm encourages Peabody investors who suffered substantial losses to submit your losses now.
Class Period: Oct. 14, 2024 – May 4, 2026
Lead Plaintiff Deadline: Aug. 24, 2026
Visit: www.hbsslaw.com/investor-fraud/btu
Contact the Firm Now: [email protected]
844-916-0895
Peabody Energy Corporation (BTU) Securities Class Action:
Peabody characterizes itself as a leading producer of metallurgical and thermal coal and has promoted Centurion, its underground longwall metallurgical coal mine in Queensland, Australia. According to the company, the mine commenced full-scale production in February 2026.
The litigation is focused on the propriety of Peabody's statements about Centurion's operational status and production capabilities.
For example, Peabody's management informed investors on February 5, 2026 that "the team was installing the very last shield and putting the finishing touches on the Centurion Mine[,]" and "our team is charged up and has started mining some of the best metallurgical coal in the world." The company and its management also assured investors that Centurion is "going to ramp up probably about 700,000 tons in Q1, about 1 million to 1.1 million tons in Q2 and Q3, and then it'll fall back down in Q4 as we have a longwall move." In response, the market rewarded these statements by sending the price of Peabody shares up about 7.8% the next day.
Just a few weeks later, on March 30, 2026, Peabody filed a current report with the SEC and abruptly disclosed that Centurion "is expected deliver approximately 250,000 tons in the first quarter[.]" In other words, the company slashed Centurion production by about 64%. The news sent the price of Peabody shares down almost 10%.
Then, on May 5, 2026, Peabody reported its Q1 2026 financial results. Of particular concern pertaining to Centurion, management revealed the truth about why it slashed the mine's Q1 production assurance.
Despite telling investors in February that it was mining Centurion and would produce 700,000 tons in Q1, a new narrative emerged – "as part of our commissioning in February, we encountered temporary mechanical and electrical issues" – and "[a]s a result, our full year sales outlook for Centurion is now 2.5 million tons compared to our original expectation of 3.5 million tons." This full year 28% reduction helped send the price of Peabody shares down nearly 6%.
"We're focused on whether Peabody and its management were sufficiently transparent about Centurion's operational capabilities during the Class Period and, if not, whether they violated federal securities laws," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in Peabody Energy and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now.
If you'd like more information and answers to other frequently asked questions about the Peabody case and the firm's investigation, read more.
Whistleblowers: Persons with non-public information regarding Peabody Energy should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Valero Energy (VLO - Free Report) ended the recent trading session at $266.22, demonstrating a -1.52% change from the preceding day's closing price. This change lagged the S&P 500's 0.45% loss on the day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, lost 1.16%.
Shares of the oil refiner have appreciated by 4.62% over the course of the past month, outperforming the Oils-Energy sector's loss of 5.87%, and the S&P 500's gain of 2.14%.
The investment community will be paying close attention to the earnings performance of Valero Energy in its upcoming release. The company is slated to reveal its earnings on July 30, 2026. The company is expected to report EPS of $8.5, up 272.81% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $35.92 billion, up 20.18% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $28.37 per share and a revenue of $134.62 billion, indicating changes of +167.39% and +9.73%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Valero Energy. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 6.86% rise in the Zacks Consensus EPS estimate. Right now, Valero Energy possesses a Zacks Rank of #3 (Hold).
In the context of valuation, Valero Energy is at present trading with a Forward P/E ratio of 9.53. This denotes a premium relative to the industry average Forward P/E of 9.35.
We can additionally observe that VLO currently boasts a PEG ratio of 0.37. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Oil and Gas - Refining and Marketing industry had an average PEG ratio of 0.37 as trading concluded yesterday.
The Oil and Gas - Refining and Marketing industry is part of the Oils-Energy sector. With its current Zacks Industry Rank of 54, this industry ranks in the top 22% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Clear Secure (YOU - Free Report) closed the most recent trading day at $55.91, moving -1.46% from the previous trading session. This change lagged the S&P 500's daily loss of 0.45%. Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw a decrease of 1.16%.
Coming into today, shares of the airport security company had gained 3.2% in the past month. In that same time, the Computer and Technology sector gained 0.38%, while the S&P 500 gained 2.14%.
The upcoming earnings release of Clear Secure will be of great interest to investors. It is anticipated that the company will report an EPS of $0.44, marking a 69.23% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $270.25 million, up 23.14% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.79 per share and revenue of $1.1 billion, indicating changes of +59.82% and +22.22%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Clear Secure should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.28% higher within the past month. Currently, Clear Secure is carrying a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Clear Secure has a Forward P/E ratio of 31.79 right now. This indicates a premium in contrast to its industry's Forward P/E of 19.77.
The Internet - Software industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 95, this industry ranks in the top 39% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Progressive (PGR - Free Report) closed the most recent trading day at $234.40, moving +1.18% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.45%. Elsewhere, the Dow lost 0.25%, while the tech-heavy Nasdaq lost 1.16%.
The insurer's stock has climbed by 15.69% in the past month, exceeding the Finance sector's gain of 5.72% and the S&P 500's gain of 2.14%.
Investors will be eagerly watching for the performance of Progressive in its upcoming earnings disclosure. On that day, Progressive is projected to report earnings of $4.56 per share, which would represent a year-over-year decline of 6.56%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $23.12 billion, up 6.95% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $17.26 per share and a revenue of $92.89 billion, representing changes of -5.42% and +6.84%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Progressive. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.55% higher. Progressive currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Progressive has a Forward P/E ratio of 13.42 right now. For comparison, its industry has an average Forward P/E of 12.05, which means Progressive is trading at a premium to the group.
One should further note that PGR currently holds a PEG ratio of 4.39. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. PGR's industry had an average PEG ratio of 2.52 as of yesterday's close.
The Insurance - Property and Casualty industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 108, placing it within the top 44% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
In the latest trading session, Analog Devices (ADI - Free Report) closed at $379.03, marking a -2.52% move from the previous day. This move lagged the S&P 500's daily loss of 0.45%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 1.16%.
The semiconductor maker's shares have seen a decrease of 3.73% over the last month, not keeping up with the Computer and Technology sector's gain of 0.38% and the S&P 500's gain of 2.14%.
Investors will be eagerly watching for the performance of Analog Devices in its upcoming earnings disclosure. On that day, Analog Devices is projected to report earnings of $3.33 per share, which would represent year-over-year growth of 62.44%. Meanwhile, the latest consensus estimate predicts the revenue to be $3.93 billion, indicating a 36.28% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $12.41 per share and a revenue of $14.58 billion, indicating changes of +59.31% and +32.29%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Analog Devices. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Analog Devices possesses a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Analog Devices is currently trading at a Forward P/E ratio of 31.33. This expresses a discount compared to the average Forward P/E of 52.25 of its industry.
Meanwhile, ADI's PEG ratio is currently 1.09. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Semiconductor - Analog and Mixed industry had an average PEG ratio of 1.01.
The Semiconductor - Analog and Mixed industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 16, putting it in the top 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Stock screening is commonly deployed by investors to ‘cut through the noise.’ The approach is especially useful when considering the thousands of options to choose from, which can often overwhelm investors.
Taking a different angle, screening is essentially the same idea as constructing a grocery list. A list helps you easily navigate a store, allowing you to quickly find what you’re looking for without wasting a chunk of time.
Still, screening is often seen as overwhelming and confusing, particularly when investors are unsure what to look for in a company. In addition, it’s not as simple as a one-screen-fits-all approach, as market participants all have different preferences.
Let’s take a closer look at screening and a few parameters available at Zacks that investors can deploy to find the stocks that they want.
Screening Parameters
Parameters can be seen as the ‘ingredients’ of a recipe, excluding any irrelevant information. Digging deeper, parameters can be fine-tuned for any investing style, whether that be momentum, value, growth, or income-based.
Value Investing
Value investors can add several parameters to their screens to find high-quality stocks trading at a discount. A few of these include the Price-to-Earnings (P/E) ratio, the Price-to-Sales (P/S) ratio, and the Price-to-Book (P/B) ratio. Zacks has several premium screens tailored toward value-focused strategies that have these parameters built in.
Momentum Investing
Momentum investing is all about riding the current trend, jumping into stocks that have enjoyed buying pressure. A few parameters investors can deploy for momentum-focused screens include the percentage price change in the stock over the last month, average volume, and price as a percentage of the 52-week high-low range. Zacks has many momentum-based screens with these parameters built in.
Growth Investing
Growth-oriented strategies are aimed at companies expected to grow their sales and earnings at an above-average level, a development that commonly leads to share outperformance. A few key parameters for growth investors include last year’s earnings and sales growth rates, expected growth rates for the current year, and the long-term expected EPS growth rate.
One of the Zacks premium growth screens provided us with a few stocks upon running: Dell Technologies (DELL - Free Report) and Analog Devices (ADI - Free Report) – two great examples of companies that have enjoyed rapid growth.
Income Investing
Income-focused investing is all about passive income, with dividend-paying stocks commonly being more ‘stable.’ Many dividend-paying companies are mature and, at the end of their growth cycle, opting to share profits with shareholders rather than reinvesting for the future. A few parameters investors can deploy when searching for dividend-paying stocks include current dividend yield and the 5-year historical dividend growth rate. No different than those above, Zacks already has several premium income-focused screens available for use.
Bottom Line
Screens are very useful tools for investors to filter out the noise, allowing for full focus on preferred parameters. The process can often be overwhelming, though, with some unsure of what parameters to include.
However, for those not interested in building out an individual screen, Zacks has many pre-built screens tailored toward common strategies, a list that includes growth, value, momentum, and income.
In the latest close session, Vertiv Holdings Co. (VRT - Free Report) was down 4.05% at $305.58. This change lagged the S&P 500's 0.45% loss on the day. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 1.16%.
The stock of company has risen by 5.96% in the past month, leading the Computer and Technology sector's gain of 0.38% and the S&P 500's gain of 2.14%.
Market participants will be closely following the financial results of Vertiv Holdings Co. in its upcoming release. The company's earnings per share (EPS) are projected to be $1.43, reflecting a 50.53% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $3.38 billion, up 27.94% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $6.38 per share and a revenue of $13.73 billion, representing changes of +51.9% and +34.24%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Vertiv Holdings Co. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.23% higher. Vertiv Holdings Co. is holding a Zacks Rank of #2 (Buy) right now.
In terms of valuation, Vertiv Holdings Co. is currently trading at a Forward P/E ratio of 49.93. This indicates a premium in contrast to its industry's Forward P/E of 12.65.
Also, we should mention that VRT has a PEG ratio of 1.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Computers - IT Services industry held an average PEG ratio of 1.02.
The Computers - IT Services industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 105, finds itself in the top 43% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
